Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations

Int J Neurosci. 2017 Mar;127(3):276-284. doi: 10.1080/00207454.2016.1194274. Epub 2016 Jun 27.

Abstract

Background: Spirometry patterns suggesting restrictive and obstructive pulmonary dysfunction have been reported in Parkinson's disease (PD). However, the patterns' precise relation to PD pathophysiology remains unclear. Purpose/Aim. To assess ON- versus OFF-state pulmonary function, the quality of its spirometric evaluation, and the quality of longitudinal spirometric findings in a large sample of PD patients with motor fluctuations.

Methods: During a placebo-controlled trial of an inhaled levodopa formulation, CVT-301, in PD patients with ≥2 h/d of OFF time, spirometry was performed by American Thoracic Society (ATS) guidelines at screening and throughout the 4-week treatment period.

Results: Among 86 patients, mean motor impairment during an OFF state at screening was moderately severe. However, mean spirometry results at screening were within normal ranges, and in a mixed model for repeated measures (MMRM), the results at screening were not dependent on motor state (ON vs. OFF). In the placebo group (n = 43), 76% of ON-state and 81% of OFF-state examinations throughout the study met ATS quality metrics, and in an MMRM analysis, mean findings at these patients' arrivals for treatment-period visits showed no significant 4-week change. Across all 86 patients, flow-volume curves prior to any study-drug administration showed only a 3% incidence of "sawtooth" morphology.

Conclusions: In PD patients with motor fluctuations, longitudinal spirometry of acceptable quality was generally obtained. Although mean findings were normal, about a quarter of spirograms did not meet ATS quality criteria. Spirogram morphology may be less indicative of various forms of respiratory dysfunction than has previously been reported in PD.

Keywords: CVT-301; Parkinson's disease; levodopa; pulmonary function; spirometry.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Levodopa / pharmacology
  • Levodopa / therapeutic use
  • Lung Diseases* / diagnosis
  • Lung Diseases* / drug therapy
  • Lung Diseases* / etiology
  • Male
  • Middle Aged
  • Motor Activity / drug effects
  • Motor Activity / physiology*
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy
  • Retrospective Studies
  • Severity of Illness Index
  • Spirometry
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Levodopa